poisar

Stocks · News reference

Canaccord Genuity Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $303

Benzinga Newsdesk

Canaccord Genuity analyst Whitney Ijem initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $303.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BLTE
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Belite Bio Announces Uplisting to the Nasdaq Global Select Market

    Belite Bio, Inc. (NASDAQ: BLTE) announced its uplisting from the Nasdaq Capital Market to the Nasdaq Global Select Market, effective October 19, 2026. The company, a clinical-stage drug developer focused on retinal diseases, achieved this milestone by meeting the higher financial and liquidity standards required. The uplisting is expected to enhance visibility among institutional investors, improve liquidity, and broaden market recognition as the company continues advancing tinlarebant, its lead candidate for Stargardt disease treatment.

    BLTE